Highlights

  • Hydration Pharmaceuticals raised approximately AUD 392,000 through a share placement.
  • The company completed a broad board and management renewal during June 2026.
  • Annual cash costs are expected to decline by approximately AUD 500,000 following the restructuring.
  • Management remains focused on expanding the US Hydralyte business.

Hydration Pharmaceuticals Company Limited (ASX:HPC) has undertaken a significant leadership and corporate restructuring as it seeks to strengthen its financial position and sharpen its operational focus. The company combined a modest capital raising with changes across its board and executive team, while introducing cost-saving measures designed to extend available cash resources. The initiatives follow the company's strategic shift towards operating solely within the United States after divesting its international Hydralyte assets in 2024.

Capital Raising Supports Working Capital

On 15 June 2026, Hydration Pharmaceuticals announced a placement of 98 million fully paid ordinary shares at AUD 0.004 per share, raising approximately AUD 392,000 before costs.

Alongside the placement, the company proposed issuing 49 million options on a one-for-two basis, subject to shareholder approval.

Management stated that the funds would primarily support working capital requirements and help maintain sales momentum across the continuing US operations, particularly through established e-commerce channels.

The capital raising was presented as funding for ongoing operations rather than expansion into new markets or product categories.

Board and Management Undergo Major Renewal

The capital raising coincided with significant leadership changes across the organisation.

Long-serving Chief Executive Officer Oliver Baker stepped down from the role and transitioned into a consulting position, while Emily Lease was appointed General Manager to oversee day-to-day commercial operations.

At board level, Non-Executive Chair Adem Karafili and director Joseph Constable resigned. They were succeeded by George Karafotias and Nick Katiforis, with Nick Berry becoming Non-Executive Chair.

The company described the appointments as part of a broader governance and operational reset.

Cost Reduction Forms Part of the Strategy

In addition to raising fresh capital, Hydration Pharmaceuticals introduced measures aimed at reducing operating expenditure.

Board remuneration is expected to decrease from approximately AUD 243,000 annually to around AUD 120,000, while broader restructuring initiatives are forecast to reduce annual cash costs by approximately AUD 500,000.

Management indicated that the savings are intended to provide greater financial flexibility while supporting the company's continuing US business operations.

The restructuring follows several years of operational challenges and efforts to streamline the business.

US Hydralyte Business Remains the Focus

Hydration Pharmaceuticals now operates as a US-focused consumer health company following the sale of its non-US Hydralyte operations during 2024.

The transaction enabled repayment of debt while allowing the company to concentrate resources on the North American hydration products market.

Future updates are expected to centre on sales performance, e-commerce growth, operational execution and the impact of the recent leadership changes.

The latest announcement represents a financial and governance restructuring rather than the launch of new products or expansion into additional markets.

What Investors May Watch

Investors may monitor US sales performance, execution of cost-saving initiatives, progress under the new leadership team, cash position, e-commerce growth and future ASX announcements.

Risks

Hydration Pharmaceuticals remains exposed to funding requirements, execution risk, competitive consumer health markets, dependence on the US business, potential shareholder dilution, operational turnaround risk and broader consumer spending conditions.